ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- ADT and activation of HGF and WNT axes in double-null prostate cancer.Nature reviews. Urology · 2026Review
- The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies.Cancers · 2026Review
- Review
- B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer.iScience · 2022Article
- Prognostic utility of the ovarian cancer secretome: a systematic investigation.Archives of gynecology and obstetrics · 2022Review
- Urinary cMet as a prognostic marker in immunoglobulin A nephropathy.Journal of cellular and molecular medicine · 2020Article
- Article
- cMet agonistic antibody attenuates apoptosis in ischaemia-reperfusion-induced kidney injury.Journal of cellular and molecular medicine · 2020Article
- Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.The Journal of biological chemistry · 2020Article
- Approaches to urinary detection of prostate cancer.Prostate cancer and prostatic diseases · 2019Review
- Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.The Journal of biological chemistry · 2018Article
- Hepatocyte growth factor/MET in cancer progression and biomarker discovery.Cancer science · 2017Review
- SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.Prostate cancer and prostatic diseases · 2017Article
- SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis.Oncotarget · 2016Article
- Article
- Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis.Human cell · 2015Article
- Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.BMC cancer · 2014Article
- Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.Biomarkers in medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeMetastatic prostate cancer is a major cause of death of men in the United States. Expression of met, a receptor tyrosine kinase, has been associated with progression of prostate cancer. EXPERIMENTAL
designTo investigate met as a biomarker of disease progression, urinary met was evaluated via ELISA in men with localized (n = 75) and metastatic (n = 81) prostate cancer. Boxplot analysis was used to compare the distribution of met values between each group. We estimated a receiver operating characteristic curve and the associated area under the curve to summarize the diagnostic accuracy of met for distinguishing between localized and metastatic disease. Protein-protein interaction networking via yeast two-hybrid technology supplemented by Ingenuity Pathway Analysis and Human Interactome was used to elucidate proteins and pathways related to met that may contribute to progression of disease.
resultsMet distribution was significantly different between the metastatic group and the group with localized prostate cancer and people with no evidence of cancer (P < 0.0001). The area under the curve for localized and metastatic disease was 0.90, with a 95% confidence interval of 0.84 to 0.95. Yeast two-hybrid technology, Ingenuity Pathway Analysis, and Human Interactome identified 89 proteins that interact with met, of which 40 have previously been associated with metastatic prostate cancer.
conclusionUrinary met may provide a noninvasive biomarker indicative of metastatic prostate cancer and may be a central regulator of multiple pathways involved in prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.